Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.33 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1653829 | 0.98 | KDM4E (0.40) | KDM4EMAPK1HIF1AEPHX2MEN1 | |
| SCHEMBL2549287 | 0.94 | KDM4E (0.33) | KDM4EMAPK1HIF1AEPHX2MEN1 | |
| SCHEMBL19002622 | 0.78 | KDM4E (0.54) | KDM4EMAPK1HIF1AALDH1A1ADRA1A | |
| SCHEMBL1654415 | 0.75 | TDP1 (0.58) | MEN1KMT2AEPHX1 | |
| SCHEMBL1654402 | 0.75 | LMNA (0.48) | MEN1KMT2AALDH1A1 | |
| SCHEMBL3174690 | 0.75 | KDM4E (0.50) | KDM4EMAPK1HIF1AMEN1KMT2A | |
| SCHEMBL11924793 | 0.74 | TDP1 (0.61) | MEN1KMT2A | |
| SCHEMBL18713243 | 0.74 | EPHX2 (0.43) | KDM4EMAPK1HIF1AEPHX2MEN1 | |
| SCHEMBL691823 | 0.73 | KDM4E (0.46) | KDM4EMAPK1HIF1AMEN1KMT2A | |
| SCHEMBL20665407 | 0.73 | CYP2C19 (0.44) | MAPK1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716293-B2 | Macrocyclic integrase inhibitors | JANSSEN R&D IRELAND (IE) | 2014-05-06 | — | — | US | disclosed |
| EP-2552923-B1 | MACROCYCLIC INTEGRASE INHIBITORS | JANSSEN R & D IRELAND (IE) | 2014-03-26 | — | — | EP | disclosed |
| US-20130035341-A1 | MACROCYCLIC INTEGRASE INHIBITORS | JANSSEN R&D IRELAND (IE) | 2013-02-07 | — | — | US | disclosed |
| EP-2552923-A1 | MACROCYCLIC INTEGRASE INHIBITORS | Janssen R&D Ireland (IE) | 2013-02-06 | — | — | EP | disclosed |
| CN-102574854-A | Macrocyclic integrase inhibitors | ELANCO ANIMAL HEALTH IRELAND | 2012-07-11 | — | — | CN | disclosed |
| WO-2011121105-A1 | MACROCYCLIC INTEGRASE INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035341-A1 | MACROCYCLIC INTEGRASE INHIBITORS | TYMP, PIM1, TYMS | KDM4E 911/4885MAPK1 2190/4885HIF1A 4460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.